Robert James Glynn, Sc.D., Ph.D.
This page shows the publications co-authored by Robert Glynn and Aruna Pradhan.
Rationale and design of the Pemafibrate to Reduce Cardiovascular Outcomes by Reducing Triglycerides in Patients with Diabetes (PROMINENT) study. Am Heart J. 2018 12; 206:80-93.
Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet. 2012 Aug 11; 380(9841):565-71.
The relative importance of systolic versus diastolic blood pressure control and incident symptomatic peripheral artery disease in women. Vasc Med. 2011 Aug; 16(4):239-46.
Hemoglobin A1c level and future cardiovascular events among women. Arch Intern Med. 2004 Apr 12; 164(7):757-61.
Adverse Effects of Low-Dose Methotrexate: A Randomized Trial. Ann Intern Med. 2020 03 17; 172(6):369-380.
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. N Engl J Med. 2019 02 21; 380(8):752-762.
Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. J Am Coll Cardiol. 2018 05 29; 71(21):2392-2401.
Predisposing factors associated with development of persistent compared with paroxysmal atrial fibrillation. J Am Heart Assoc. 2014 May 01; 3(3):e000916.
Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013 Aug; 166(2):199-207.e15.
Socioeconomic status and incident type 2 diabetes mellitus: data from the Women's Health Study. PLoS One. 2011; 6(12):e27670.
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.